Speakers

Expand/Collapse

Ercem Atillasoy
Chief Regulatory & Safety Officer
AlloVir

Day One

Wednesday April 21

11:40 am | Expedited Regulatory Pathways for Development & Licensure of Novel Anti-Infectives

12:30 pm | Q&A/Discussion

Martin Everett
Chief Scientific Officer
AntaBio

Day One

Wednesday April 21

4:00 pm | Pseudomonas Elastase (LasB) as a Therapeutic Target

4:50 pm | Q&A/Discussion

Glenn Dale
Chief Development Officer
BioVersys

Day Two

Thursday April 22

11:15 am | BV100 – a Novel Therapy for Antibiotic-Resistant Acinetobacter Infections

12:30 pm | Q&A/Discussion

Kevin Outterson
Executive Director & Professor of Law
CARB-X & Boston University

Day One

Wednesday April 21

9:25 am | Surviving FDA Approval of your Antibiotic

10:15 am | Q&A/Discussion

Cara Cassino
Executive Vice President of R&D & Chief Medical Officer
ContraFect

Day Two

Thursday April 22

9:00 am | Direct Lytic Agents (DLA): New Medical Modalities for Life- Threatening, Drug-Resistant Infections

9:50 am | Q&A/Discussion

David Altarac
Chief Medical Officer
Entasis Therapeutics

Day Two

Thursday April 22

12:05 pm | Targeted Therapy for Rare Pathogens: Challenges & Opportunities

12:30 pm | Q&A/Discussion

Dave Ousterout
Chief Scientific Officer
Locus Biosciences

Day One

Wednesday April 21

3:05 pm | Q&A/Discussion

1:50 pm | Clinical Experience with crPhage in Urinary Tract Infections

Silas Holland
Head of External Affairs (Interim) & Director of Global Public Policy
The AMR Action Fund & Merck

Day One

Wednesday April 21

9:00 am | AMR Action Fund: Strengthening & Accelerating Antibiotic Development

10:15 am | Q&A/Discussion

Mike Gordeev
Chief Scientific Officer
MicuRx Pharmaceuticals

Day Two

Thursday April 22

2:10 pm | Novel Investigational Polymyxin MRX-8 with an Improved Safety & Efficacy against Key Gram-Negative Infections

3:25 pm | Q&A/Discussion

John George
Co-Founder & Chief Scientific Officer
Oppilotech

Day Two

Thursday April 22

3:25 pm | Q&A/Discussion

3:00 pm | Computational Modelling to Aid Target Discovery

Jonathan Steckbeck
Founder, President & Chief Executive Officer
Peptilogics

Day One

Wednesday April 21

12:05 pm | Differentiated Approach to Harnessing Novel Biologics & Overcome AMR

12:30 pm | Q&A/Discussion

Jeanette Mucha
Chief Executive Officer & Co- Founder
SciBac

Day One

Wednesday April 21

3:05 pm | Q&A/Discussion

2:40 pm | Fighting Fire with Fire: Live Biotherapeutics for Pulmonary Infections

Angela Talley
Vice President of Clinical Development
Spero Therapeutics

Day Two

Thursday April 22

11:40 am | Ensuring Anti-Infective Economic Sustainability by Targeting the Unmet Medical Need

12:30 pm | Q&A/Discussion

David Powell
Chief Scientific Officer
Summit Therapeutics

Day Two

Thursday April 22

9:25 am | Building a Pipeline of New Mechanism Antibiotics that Drives Commercial Sustainability through Clinical Superiority

9:50 am | Q&A/Discussion

Nrusingh Mohapatra
Chief Scientific Officer
Techulon

Day Two

Thursday April 22

1:45 pm | Obstacles for Discovery & Development of Narrow Spectrum Antimicrobials

3:25 pm | Q&A/Discussion

Joseph DiMasi
Director of Economic Analysis
Tufts CSDD

Day One

Wednesday April 21

9:50 am | Trends in the Development & Approval of New Anti-infectives: Cycle Times, Success Rates & Expedited Regulatory Pathways

10:15 am | Q&A/Discussion

Silvia Caballero
Associate Director of Infectious Diseases
Vedanta Biosciences

Day One

Wednesday April 21

4:25 pm | Live Bacterial Consortia, a Novel Microbiome- Based Approach for Infection Prevention

4:50 pm | Q&A/Discussion

James Crowe
Director
Vanderbilt Vaccine Center

Day One

Wednesday April 21

2:15 pm | Human Monoclonal Antibodies for Emerging Infections

3:05 pm | Q&A/Discussion

Mohammad Seyedsayamdost
Associate Professor of Chemistry & Molecular Biology
Princeton University

Day Two

Thursday April 22

3:25 pm | Q&A/Discussion

2:35 pm | Cryptic Metabolites as a New Source of Pharmaceutical Leads

Peter Beyer
Senior Advisor and Team Lead
World Health Organization - WHO

Day One

Wednesday April 21

8:30 am | Keynote Presentation: A Review of the Antibacterial Development Pipeline

Steve Sandor
VP, Market Access and Trade
PARATEK PHARMACEUTICALS

Day One

Wednesday April 21

8:20 am | Chair’s Opening Remarks

10:15 am | Q&A/Discussion

12:30 pm | Q&A/Discussion

John White
Vice President, Business Strategy and Commercial Operations
PARATEK PHARMACEUTICALS

Day Two

Thursday April 22

8:50 am | Chair’s Opening Remarks

9:50 am | Q&A/Discussion

12:30 pm | Q&A/Discussion